It suggests that celecoxib administration as adjuvant therapy or in combination with PI3K/AKT inhibitors and/or IGF-1R inhibitors could be of therapeutic benefit for patients with NSCLC. This evidence concerns the gene IGF1R and non-small cell lung carcinoma.